文献速递中毒与环境急症消化、代谢与肾脏急症

对乙酰氨基酚中毒五十年:1973-2023年风险评估与治疗的发展,特别关注爱丁堡和丹佛发表的贡献

Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973-2023 with particular focus on contributions published from Edinburgh and Denver.
PubMed 文献 · Clin Toxicol (Phila) · 2024-01-25
一句话结论回顾50年对乙酰氨基酚中毒风险评估与乙酰半胱氨酸治疗演变,Rumack-Matthew列线图治疗线选择影响治疗人数,最佳剂量仍不确定。

该综述检索PubMed及其子数据库1963-2023年共1,166篇文献,聚焦170篇风险评估、141篇乙酰半胱氨酸不良反应和114篇不同方案文献,主要基于作者在爱丁堡和丹佛的贡献。1971年确立对乙酰氨基酚剂量与毒性风险关系并发展Rumack-Matthew列线图;1973年阐明毒性机制为环氧化物代谢物共价结合。乙酰半胱氨酸方案从负荷量150 mg/kg(15分钟或1小时)、50 mg/kg(4小时)、100 mg/kg(16小时)发展为更慢负荷方案;英国2012年将治疗线降至4小时100 mg/L(662 µmol/L)。最佳剂量、早期识别高危患者和迟就诊者治疗仍不确定。

要点

  • Rumack-Matthew列线图基于爱丁堡数据建立,美国国家多中心研究采用4小时150 mg/L(992 µmol/L)治疗线,澳大利亚和新西兰随后采用。
  • 英国2012年将4小时治疗线从200 mg/L(1,323 µmol/L)降至100 mg/L(662 µmol/L),增加入院和治疗人数且成本高。
  • 早期静脉乙酰半胱氨酸方案为负荷量150 mg/kg(15分钟或1小时)、50 mg/kg(4小时)、100 mg/kg(16小时),与恶心、呕吐和过敏样反应相关。
  • 苏格兰和纽卡斯尔止吐预处理方案为100 mg/kg(2小时)后200 mg/kg(10小时),在英国广泛采用,队列比较提示疗效与标准方案相当。
  • 无乙酰半胱氨酸剂量范围研究和安慰剂对照研究,极大过量时最佳剂量不确定;风险评估生物标志物尚未进入临床试验。

适用人群与场景

  • 对乙酰氨基酚(扑热息痛)中毒患者,包括单次过量摄入和多次( staggered)摄入。

诊断标准与关键阈值

  • Rumack-Matthew列线图用于风险评估:美国国家多中心研究治疗线从过量后4小时150 mg/L(992 µmol/L)开始,延伸至24小时,半衰期4小时,现为美国标准并在澳大利亚和新西兰采用。
  • 英国治疗线最初为4小时200 mg/L(1,323 µmol/L)(Rumack-Matthew「风险」线),2012年英国药品和健康产品管理局将所有患者4小时治疗线降至100 mg/L(662 µmol/L)。

处置流程与药物剂量

  • 早期英国及随后美国使用的静脉乙酰半胱氨酸方案:负荷量150 mg/kg(15分钟或1小时),随后50 mg/kg(4小时),再100 mg/kg(16小时)。
  • 苏格兰和纽卡斯尔止吐预处理方案:乙酰半胱氨酸100 mg/kg(2小时)后200 mg/kg(10小时),已在英国广泛采用,队列比较提示疗效与标准方案相当,并为选择性更高剂量乙酰半胱氨酸提供机会。
  • 口服乙酰半胱氨酸是美国国家多中心研究试验的解毒剂。

研究设计与关键结果

  • 综述检索PubMed及其子数据库1963-2023年共1,166篇文献,聚焦170篇风险评估、141篇乙酰半胱氨酸不良反应和114篇不同乙酰半胱氨酸方案文献,主要基于作者在爱丁堡和丹佛的贡献。
  • 1971年确立对乙酰氨基酚剂量与毒性风险的关键关系,并基于爱丁堡数据发展Rumack-Matthew列线图。
  • 1973年系列论文阐明毒性机制:对乙酰氨基酚肝毒性由毒性中间体环氧化物代谢物形成引起,该代谢物通常由谷胱甘肽解毒,过量时共价结合肝酶和蛋白质。
  • 早期静脉乙酰半胱氨酸方案(负荷量150 mg/kg、50 mg/kg、100 mg/kg)与药物不良反应(恶心、呕吐和过敏样反应)相关,导致治疗中断;较新方案给予更慢的负荷量。
  • 英国2012年降低治疗线增加入院和治疗人数且成本高;美国国家多中心研究治疗线为4小时150 mg/L(992 µmol/L),现为美国标准并在澳大利亚和新西兰采用。
  • 无乙酰半胱氨酸剂量范围研究和安慰剂对照研究,极大过量时最佳剂量不确定;风险评估生物标志物尚未进入临床试验。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 选择Rumack-Matthew列线图干预浓度对治疗患者比例有重要影响,需结合当地治疗线(美国4小时150 mg/L;英国4小时100 mg/L)进行风险评估。
  • 苏格兰和纽卡斯尔止吐预处理方案(100 mg/kg 2小时+200 mg/kg 10小时)在英国广泛采用,队列比较提示疗效与标准方案相当,并为选择性更高剂量乙酰半胱氨酸提供机会。
  • 对乙酰氨基酚极大过量患者和多次(staggered)摄入者的最佳乙酰半胱氨酸剂量、高危患者早期识别及迟就诊者的最佳治疗仍是未确定领域。

指南或共识出处

  • Rumack-Matthew列线图(基于爱丁堡数据)。
  • 美国国家多中心研究。
  • 苏格兰和纽卡斯尔止吐预处理方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Fifty years ago, basic scientific studies and the availability of assay methods made the assessment of risk in paracetamol (acetaminophen) poisoning possible. The use of the antidote acetylcysteine linked to new methods of risk assessment transformed the treatment of this poisoning. This review will describe the way in which risk assessment and treatments have developed over the last 50 years and highlight the remaining areas of uncertainty.

METHODS: A search of PubMed and its subsidiary databases revealed 1,166 references published in the period 1963-2023 using the combined terms "paracetamol", "poisoning", and "acetylcysteine". Focused searches then identified 170 papers dealing with risk assessment of paracetamol poisoning, 141 with adverse reactions to acetylcysteine and 114 describing different acetylcysteine regimens. To manage the extensive literature, we focused mainly on contributions made by the authors during their time in Edinburgh and Denver.

DOSE AND CONCENTRATION RESPONSE: The key relationship between paracetamol dose and toxicity risk was established in 1971 and led to the development of the Rumack-Matthew nomogram from data collected in Edinburgh.

MECHANISMS OF TOXICITY: A series of papers on the mechanisms of toxicity were published in 1973, and these showed that paracetamol hepatotoxicity was caused by the formation of a toxic intermediate epoxide metabolite normally detoxified by glutathione but which, in excess, was bound covalently to hepatic enzymes and proteins. An understanding of the relationship between the rate of paracetamol metabolism, paracetamol concentration, and toxic hazard in humans soon followed.

ANTIDOTE DEVELOPMENT AND EFFICACY IN PATIENTS: These discoveries were followed by the testing of a range of sulfhydryl-donors in animals and "at risk" patients. Acetylcysteine was developed as the lead intravenous antidote in the United Kingdom. The license holder in the United States refused to make an intravenous formulation. Thus, oral acetylcysteine became the antidote trialed in the United States National Multicenter Study. Intravenous acetylcysteine regimens used initially in the United Kingdom and subsequently in the United States used loading doses of 150 mg/kg over 15 minutes or one hour, 50 mg/kg over four hours, and 100 mg/kg over 16 hours. These regimens were associated with adverse drug reactions (nausea, vomiting and anaphylactoid reactions) and hence, treatment interruption. Newer dosing regimens now give loading doses more slowly. One, the Scottish and Newcastle Anti-emetic Pretreatment protocol, using an acetylcysteine regimen of 100 mg/kg over two hours followed by 200 mg/kg over 10 hours, has been widely adopted in the United Kingdom. A cohort comparison study suggests this regimen has comparable efficacy to standard regimens and offers opportunities for selective higher acetylcysteine dosing.

RISK ASSESSMENT AT PRESENTATION: No dose-ranging studies with acetylcysteine were done, and no placebo-controlled studies were performed. Thus, there is uncertainty regarding the optimal dose of acetylcysteine, particularly in patients ingesting very large overdoses of paracetamol. The choice of intervention concentration on the Rumack-Matthew nomogram has important consequences for the proportion of patients treated. The United States National Multicenter Study used a "treatment" line starting at 150 mg/L (992 µmol/L) at 4 hours post overdose, extending to 24 hours with a half-life of 4 hours, now standard there, and subsequently adopted in Australia and New Zealand. In the United Kingdom, the treatment line was initially 200 mg/L (1,323 µmol/L) at 4 hours (the Rumack-Matthew "risk" line). In 2012, the United Kingdom Medicines and Healthcare products Regulatory Agency lowered the treatment line to 100 mg/L (662 µmol/L) at 4 hours for all patients, increasing the number of patients admitted and treated at a high cost. Risk assessment is a key issue for ongoing study, particularly following the development of potential new antidotes that may act in those at greatest risk. The development of biomarkers to assess risk is ongoing but has yet to reach clinical trials.

CONCLUSION: Even after 50 years, there are still areas of uncertainty. These include appropriate acetylcysteine doses in patients who ingest different paracetamol doses or multiple (staggered) ingestions, early identification of at-risk patients, and optimal treatment of late presenters.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Bateman DN, Dart RC, Dear JW, et al. Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973-2023 with particular focus on contributions published from Edinburgh and Denver. Clin Toxicol (Phila). 2024. PMID: 38197864. doi:10.1080/15563650.2023.2293452

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。